Literature DB >> 31024204

Relative Adrenal Insufficiency in Patients with Alcoholic Hepatitis.

Manoj Kumar1, Gaurav K Gupta1, Shashank J Wanjari1, Vijyant Tak1, Mayank Ameta1, Sandeep Nijhawan1.   

Abstract

BACKGROUND/AIMS: Alcoholic hepatitis (AH) is an acute hepatic inflammation associated with high morbidity and mortality. Treatment with steroids is known to decrease short-term mortality in severe AH patients. Hence, we hypothesize that adrenal insufficiency can be associated with severe AH and affects prognosis. The aim of this study was (1) to evaluate relative adrenal insufficiency (RAI) in patients with AH and (2) to Compare RAI with the severity of AH.
METHODS: Newly diagnosed cases of AH hospitalized in SMS Medical College and Hospital, Department of Gastroenterology were, enrolled. All patients of AH were classified as mild and severe AH on the basis of Maddrey discriminant function (DF). After baseline serum cortisol, 25 IU ACTH (Adreno Corticotrophic Hormone) was injected intramuscularly and blood sample was collected after 1 h and assessed for serum cortisol. RAI was defined as <7 μg increase in the cortisol level from baseline. RAI was compared with severity of AH.
RESULTS: Of 120 patients of AH, 58 patients fulfilled the inclusion criteria, in which 48 patients were diagnosed as severe AH and 10 patients were diagnosed as mild AH. In patients with severe AH, the baseline mean serum cortisol level was significantly high as compared with mild AH; 26 patients (54.16 %) of 48 patients with severe AH showed RAI (P ≤ 0.001).Whereas in patients with mild AH, none of patients showed RAI. RAI also showed negative correlation with DF. There was no difference in RAI with respect to acute kidney injury (AKI).
CONCLUSION: RAI is a common entity in patients with severe AH, and it is related with the severity of disease.

Entities:  

Keywords:  ACTH, Adreno Corticotrophic Hormone; AH, Alcoholic Hepatitis; AI, Adrenal Insuffiency; AKI, Acute Kidney Injury; ALD, Alcoholic Liver Disease; ALT, Alanine Aminotranferase; AST, Aspartate Aminotransferase; CIRCI (Critical Illness Related Corticosteroid Insufficiency); CIRCI, Critical Illness Related Corticosteroid Insufficiency; DF, Discriminant Function; HPA, Hypothalamic Pituitary Adrenal; INR, International Normalised Ratio; MELD, Model for End-stage Liver Disease; PT, Prothrombin Time; RAI, Relative Adrenal Insuffiency; TLC, Total Leucocyte Count; alcoholic hepatitis; relative adrenal insufficiency

Year:  2018        PMID: 31024204      PMCID: PMC6477128          DOI: 10.1016/j.jceh.2018.09.002

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  31 in total

Review 1.  Corticosteroid insufficiency in acutely ill patients.

Authors:  Mark S Cooper; Paul M Stewart
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

2.  Adrenocortical steroid metabolism and adrenal cortical function in liver disease.

Authors:  R E PETERSON
Journal:  J Clin Invest       Date:  1960-02       Impact factor: 14.808

3.  MELD accurately predicts mortality in patients with alcoholic hepatitis.

Authors:  Winston Dunn; Laith H Jamil; Larry S Brown; Russell H Wiesner; W Ray Kim; K V Narayanan Menon; Michael Malinchoc; Patrick S Kamath; Vijay Shah
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

4.  Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis.

Authors:  Bettina Zietz; Guntram Lock; Barbara Plach; Wolfgang Drobnik; Johannes Grossmann; Jürgen Schölmerich; Rainer Hans Straub
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-05       Impact factor: 2.566

Review 5.  Adrenal insufficiency in the critically ill: a new look at an old problem.

Authors:  Paul E Marik; Gary P Zaloga
Journal:  Chest       Date:  2002-11       Impact factor: 9.410

6.  The hepatoadrenal syndrome: a common yet unrecognized clinical condition.

Authors:  Paul E Marik; Timothy Gayowski; Thomas E Starzl
Journal:  Crit Care Med       Date:  2005-06       Impact factor: 7.598

7.  A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin.

Authors:  D Annane; V Sébille; G Troché; J C Raphaël; P Gajdos; E Bellissant
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

Review 8.  Pathogenesis, diagnosis, and treatment of alcoholic liver disease.

Authors:  K V Menon; G J Gores; V H Shah
Journal:  Mayo Clin Proc       Date:  2001-10       Impact factor: 7.616

9.  A randomized trial of prednisolone in patients with severe alcoholic hepatitis.

Authors:  M J Ramond; T Poynard; B Rueff; P Mathurin; C Théodore; J C Chaput; J P Benhamou
Journal:  N Engl J Med       Date:  1992-02-20       Impact factor: 91.245

10.  Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock.

Authors:  Ming-Hung Tsai; Yun-Shing Peng; Yung-Chang Chen; Nai-Jeng Liu; Yu-Pin Ho; Ji-Tseng Fang; Jau-Min Lien; Chun Yang; Pang-Chi Chen; Cheng-Shyong Wu
Journal:  Hepatology       Date:  2006-04       Impact factor: 17.425

View more
  4 in total

Review 1.  Current Medical Treatment for Alcohol-Associated Liver Disease.

Authors:  Gustavo Ayares; Francisco Idalsoaga; Luis A Díaz; Jorge Arnold; Juan P Arab
Journal:  J Clin Exp Hepatol       Date:  2022-02-12

2.  Outcomes of Hospitalized Acute Alcoholic Hepatitis (AH) in Patients With Bipolar 1 Disorder (B1D).

Authors:  Alexander J Kaye; Shivani Patel; Sarah Meyers; Daniel Rim; Catherine Choi; Sushil Ahlawat
Journal:  Cureus       Date:  2022-05-27

Review 3.  Emerging Noninvasive Biomarkers, and Medical Management Strategies for Alcoholic Hepatitis: Present Understanding and Scope.

Authors:  Khushboo S Gala; Vatsalya Vatsalya
Journal:  Cells       Date:  2020-02-25       Impact factor: 6.600

4.  Central role of intestinal epithelial glucocorticoid receptor in alcohol- and corticosterone-induced gut permeability and systemic response.

Authors:  Pradeep K Shukla; Avtar S Meena; Joseph F Pierre; RadhaKrishna Rao
Journal:  FASEB J       Date:  2022-01       Impact factor: 5.834

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.